2'-氟-4-联苯基甲醇 | 773872-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2'-氟-4-联苯基甲醇
• 英文名称: [4-(2-fluorophenyl)phenyl]methanol
• 英文别名: 2'-fluorobiphenyl-4-ylmethanol；2'-fluoro-4-biphenylmethanol；4-(2-Fluorophenyl)benzyl alcohol
• CAS: 773872-57-4
• 化学式: C₁₃H₁₁FO
• 分子量: 202.228
• InChiKey: WABWIEVUZWQZLC-UHFFFAOYSA-N

物化性质

• 熔点：
  57-59℃
• 沸点：
  332.1±30.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2906299090

反应信息

• 作为反应物：
  描述：

  2'-氟-4-联苯基甲醇 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以90%的产率得到2’-氟联苯-4-甲醛
  参考文献：
  名称：

  Brown, John W.; Butcher, Jane L.; Byron, David J., Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 159, p. 255 - 266

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氟联苯-4-羧酸 在 lithium aluminium tetrahydride 、 boron trifluoride methanol complex 作用下， 反应 6.0h， 生成 2'-氟-4-联苯基甲醇
  参考文献：
  名称：

  Brown, John W.; Butcher, Jane L.; Byron, David J., Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 159, p. 255 - 266

  摘要：

  DOI：

文献信息

• [EN] SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS<br/>[FR] DÉRIVÉS DE SPIRO AZÉTIDINE ISOXAZOLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DE SSTR5
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014142363A1

  公开（公告）日：2014-09-18

  Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

  提供一个具有SSTR5拮抗作用的化合物，该化合物由以下公式（1）或其盐表示：其中每个符号的定义与说明书中相同。
• CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20160068482A1

  公开（公告）日：2016-03-10

  Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

  本文描述了一些化合物和药物组成物，它们可以抑制N-酰基乙醇胺酸酰化酶（NAAA）。本文还描述了合成这些化合物的方法，以及将它们制成药物组成物的方法。同时，本文还描述了抑制NAAA以维持棕榈酰乙醇胺（PEA）和其他N-酰基乙醇胺（NAE）的水平的方法，这些物质是NAAA的底物，并且在NAE浓度降低的情况下有用。此外，本文还描述了治疗和缓解疼痛、炎症、炎症性疾病和其他疾病的方法，这些疾病中脂肪酸乙醇胺的调节在临床或治疗上是相关的，或者NAE的浓度降低与该疾病有关。
• LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT
  申请人：JNC Corporation

  公开号：EP3275973A1

  公开（公告）日：2018-01-31

  Subject The subject is to provide a liquid crystal composition that includes a polymerizable compound (or polymer) and a polar compound, where the homeotropic alignment of liquid crystal molecules can be achieved by the action of these compounds, and a liquid crystal display device including this composition. This composition satisfies at least one of characteristics such as a high maximum temperature, a low minimum temperature, a small viscosity, a suitable optical anisotropy, a large positive dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light or heat or a large elastic constant, or is suitably balanced regarding at least two of the characteristics. The means concerns a nematic liquid crystal composition that has positive dielectric anisotropy and that includes a polymerizable compound as an first additive and a polar compound as a second additive, and the composition may include a specific liquid crystal compound having a large positive dielectric anisotropy and a specific liquid crystal compound having a high maximum temperature or a small viscosity, and concerns a liquid crystal display device including the composition.

  主题 本课题旨在提供一种液晶组合物，其中包括一种可聚合化合物（或聚合物）和一种极性化合物，通过这些化合物的作用可实现液晶分子的各向同性排列，并提供一种包括这种组合物的液晶显示装置。这种组合物至少满足以下一种特性，如最高温度高、最低温度低、粘度小、光学各向异性合适、正介电各向异性大、比电阻大、对紫外线或热的稳定性高或弹性常数大，或至少在其中两种特性方面适当平衡。 该手段涉及一种具有正介电常数的向列液晶组合物，该组合物包括作为第一添加剂的可聚合化合物和作为第二添加剂的极性化合物，该组合物可包括具有较大正介电常数的特定液晶化合物和具有较高最高温度或较小粘度的特定液晶化合物，还涉及一种包括该组合物的液晶显示设备。
• [EN] CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS<br/>[FR] DÉRIVÉS DE CARBAMATE D'INHIBITEURS D'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA) À BASE DE LACTAME
  申请人：UNIV CALIFORNIA

  公开号：WO2014144836A3

  公开（公告）日：2014-12-11
• Structure–activity relationship studies of QS11, a small molecule Wnt synergistic agonist
  作者：Manish K. Singh、Huanyao Gao、Wei Sun、Zhiquan Song、Robert Schmalzigaug、Richard T. Premont、Qisheng Zhang

  DOI：10.1016/j.bmcl.2015.06.062

  日期：2015.11

  Both the Wnt/beta-catenin signaling pathway and small GTPases of the ADP-ribosylation factors (ARF) family play important roles in regulating cell development, homeostasis and fate. The previous report of QS11, a small molecule Wnt synergist that binds to ARF GTPase-activating protein 1 (ARFGAP1), suggests a role for ARFGAP1 in the Wnt/b-catenin pathway. However, direct inhibition of enzymatic activity of ARFGAP1 by QS11 has not been established. Whether ARFGAP1 is the only target that contributes to QS11's Wnt synergy is also not clear. Here we present structure-activity relationship (SAR) studies of QS11 analogs in two assays: direct inhibition of enzymatic activity of purified ARFGAP1 protein and cellular activation of the Wnt/b-catenin pathway. The results confirm the direct inhibition of ARFGAP1 by QS11, and also suggest the presence of other potential cellular targets of QS11. (C) 2015 Elsevier Ltd. All rights reserved.